Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

The Cesarean Study: Optimizing Cesarean Sections and Improving Patient-Healthcare Provider Trust Using Evidence Informed Recommendations (CS)

torstai 6. elokuuta 2026 päivittänyt: Lund University

The Cesarean Study

Cesarean section (CS) rates have rapidly increased worldwide, with projections suggesting that by 2030, one in every three births will be by CS (1). In Sweden, rates have more than doubled from 9% in the 1990s, to 20% in 2024 (2). While CS can be a life-saving procedure when medically indicated, non-essential CS increase the risk of complications and have been linked to increased maternal morbidity and even death, neonatal respiratory issues, and longer recovery times (3). They also place added strain on already burdened healthcare systems by increasing the use of medical resources and staff capacity.

The purpose of this project is to evaluate the use of the "Cesarean Bundle", a three-part intervention designed to improve patient-clinician communication and trust.

Primary Aim: To evaluate the impact of the "Cesarean Bundle" in improving patient-clinician communication and trust compared to standard care.

Hypothesis: Use of the "Cesarean Bundle" will improve patients' trust in their healthcare providers.

Secondary Aim: To evaluate whether adoption of the "Cesarean Bundle" is associated with changes in cesarean section rates, especially among low-risk obstetric populations.

Hypothesis: Implementation of the "Cesarean Bundle" will be associated with a reduction in overall cesarean section rates, particularly among low-risk pregnancies.

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

Rising CS rates globally and across Europe pose a growing challenge to maternal-newborn health (1). In some European countries, CS rates have soared to 55%, and in Sweden, almost 20,000 procedures are performed annually, with numbers continuing to rise (2, 3). Strikingly, nearly 40% of these are planned cesareans, highlighting a critical need to change on-going clinical practices, especially for low-risk pregnancies, which are well-known drivers of CS rates (5, 6). These rates also contradict the World Health Organization's (WHOs) recommendations that CS rates above 10-15% are not associated with improved maternal-newborn outcomes (5). The WHO has provided clear guidance for reducing non-essential CS (5, 6), emphasizing evidence-based strategies such as requiring a second clinician's sign-off and fostering multidisciplinary reflection, both of which are key parts of the Cesarean study's intervention.

Qualitative evidence from Kingdon et al. (7,8) has shown that women want their birth preferences acknowledged, value individualized information, and are influenced by how health professionals communicate, making shared decision-making essential. However, studies from Quebec (9) and Spain (10) revealed that there are some persistent barriers to implementing guidelines, such as fragmented care and inconsistent messaging, which reinforce the well-known "know-do gap" where best practices fail to reach routine care. The Cesarean Study responds directly to this need, testing a three-part therapy bundle aligned with WHOs recommendations for maximal impact.

Population Pregnant women remitted to clinicians for planned CS discussion.

Intervention

The "Cesarean Bundle", a three-part, decision-support model, comprising of:

I. The Cesarean Discussion Guide, which is a structured clinical tool designed to facilitate personalized, evidence-based conversations between clinicians and patients considering planned cesarean birth. It captures key clinical data, patient values, and birth preferences, integrates risk stratification using the Robson Classification (11-13), and presents short- and long-term outcomes of cesarean versus vaginal birth in a clear, visual format. By standardizing counseling and embedding shared decision-making into routine care, the guide supports more equitable, informed, and patient-centered birth planning. The principal investigator (MZ) has developed the guide with support from Ariadne Labs, Boston USA.

II. Mandatory second opinion/team decision from another clinician for all planned cesarean requests; and, III. Regular team audits reviewing decision-making patterns.

Standard care, consisting of usual clinical consultations for discussing and approving planned CS, without structured guidance or required secondary clinician or team review.

Outcomes Primary outcome Patient-reported trust in the care team, measured by the Health Care Relationship Trust Scale-Revised (HCRTS-R) (14)

Secondary outcomes i) Change in planned CS rate before and after intervention, including subdivisions by Robson Groups for risk stratification ii) Composite of severe neonatal outcomes, including perinatal mortality, 5-min Apgar score <6, hypoxic ischemic encephalopathy grade II-III, intracranial hemorrhage, neonatal seizures, neonatal infection, hypoglycemia, respiratory distress, umbilical arterial pH< 7.05 iii) Composite of severe maternal outcomes, including postpartum hemorrhage (>1000ml), ICU admission, postpartum infection iv) Twelve question survey for clinicians and patients reporting experience of usability, acceptability, feasibility of intervention vs standard care v) Qualitative interviews using the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, and Maintenance) (15) to evaluate the impact and real-world applicability of the Cesarean Bundle across patient, partner, clinician, and system levels vi) Cost-analysis of intervention vs standard care.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

260

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

      • Malmö, Ruotsi
        • Rekrytointi
        • Skanes University Hospital
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Joo

Kuvaus

Inclusion Criteria:

  • Pregnant women aged ≥18 years
  • Referred for consultation regarding planned cesarean section
  • Able to provide informed consent (with interpreter support if needed)

Exclusion Criteria:

  • Women with an absolute medical indication for cesarean section (e.g., placenta previa), where shared decision-making is not applicable
  • Women who decline participation in the study components (e.g., surveys/interviews)

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Tukevaa hoitoa
  • Jako: Satunnaistettu
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Active Comparator: Intervention: Cesarean Bundle
Cesarean Bundle (structured discussion guide, mandatory second/team opinion, and regular team reviews/audits)

The Cesarean Bundle is a structured, three-component clinical intervention designed to support evidence-based and shared decision-making for planned cesarean sections:

  1. Cesarean Discussion Guide:

    A standardized decision-support tool used during all consultations for planned cesarean section. It incorporates clinical data, risk stratification (e.g., Robson classification), and clear information on short- and long-term risks and benefits of cesarean versus vaginal birth, while also capturing patient preferences and values.

  2. Mandatory Second/team Opinion:

    All requests for planned cesarean section require review and approval by a second clinician/team before a final decision is made.

  3. Regularl Multidisciplinary Team Meetings:

Regular team-based reviews of cases and decision-making patterns to promote consistency, reflection, and adherence to evidence-based practice.

The intervention is integrated into routine care, with minimal disruption to standard workflows, and is support

Ei väliintuloa: Control Arm
Standard care (usual clinical practice without structured tools)

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Patient-Reported Trust in the Care Team
Aikaikkuna: Pilot: 12-18 months; Actual study 48 months
Patient-Reported Trust in the Care Team Measured using the Health Care Relationship Trust Scale-Revised (HCRTS-R), a validated questionnaire assessing patients' trust in their healthcare providers following consultation for planned cesarean section. Each of the survey's 13 items is scored individually on a five-point scale (0 to 4), where the item score reflects the patient's immediate assessment of specific relational experiences, such as active listening, truth-telling, and respect for privacy. After converting one reverse-worded question to ensure that higher numbers consistently reflect stronger alignment with positive relational attributes, the individual item scores are summed to generate a cumulative total score ranging from 0 to 52. Within this spectrum, the higher the score, the better the reported trust and communication.
Pilot: 12-18 months; Actual study 48 months

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Cesarean section rates
Aikaikkuna: Pilot: 12-18 months. Actual study: 48-54 months as some cesarean section may be reported at later date after the pregnancy has led to the birth of the baby.
Using Robson Groups
Pilot: 12-18 months. Actual study: 48-54 months as some cesarean section may be reported at later date after the pregnancy has led to the birth of the baby.
Maternal outcome
Aikaikkuna: Pilot: 12-18 months. Main study: 48-54 months as some maternal outcomes may be reported at later date after the pregnancy has led to the birth of the baby.
This is a composite of whether any of the following maternal outcomes was found (Y/N): postpartum hemorrhage (> or = 1000 ml), admission to intensive care unit (ICU) admission, and postpartum infection needing antiobiotics.
Pilot: 12-18 months. Main study: 48-54 months as some maternal outcomes may be reported at later date after the pregnancy has led to the birth of the baby.
Neonatal outcome
Aikaikkuna: Pilot: 12-18 months. Actual study: 48-54 months depending on when data is available from the patient charts and once the pregnancy has led to birth of the baby
This is a composite of whether any of the following neonatal outcomes was present (Y/N): perinatal mortality, 5-minute Apgar score less than 7, hypoxic-ischemic encephalopathy (grade I-III), intracranial hemorrhage, neonatal seizures, infection, hypoglycemia, respiratory distress, and umbilical artery pH <7.05.
Pilot: 12-18 months. Actual study: 48-54 months depending on when data is available from the patient charts and once the pregnancy has led to birth of the baby
Patient-Reported Experience
Aikaikkuna: Pilot 12-18 months. Actual study 48-54 months
This is a survey that uses a 12-item questionnaire assessing acceptability, usability, and feasibility of the intervention. Total score 0-12 where 12 is the highest number and indicated best reported experience.
Pilot 12-18 months. Actual study 48-54 months

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Yhteistyökumppanit

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 5. toukokuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Keskiviikko 15. toukokuuta 2030

Opintojen valmistuminen (Arvioitu)

Maanantai 31. joulukuuta 2035

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 26. kesäkuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 6. elokuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 12. elokuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 12. elokuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Torstai 6. elokuuta 2026

Viimeksi vahvistettu

Perjantai 1. toukokuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

De-identified individual participant data (IPD) will be shared, including demographic variables (e.g., age, parity, BMI), clinical characteristics (e.g., pregnancy and delivery data, indication for cesarean section), intervention exposure, and outcome measures (e.g., planned cesarean rates, maternal and neonatal outcomes, and patient-reported trust scores).

Survey responses (e.g., HCRTS-R and acceptability/feasibility questionnaires) and relevant implementation metrics may also be included. All data will be pseudonymized, with direct identifiers removed, in accordance with GDPR and applicable data protection regulations.

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa